WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that President and CEO, Daniel Junius, will present at the J.P. Morgan 29th Annual Healthcare Conference at 9:00 am PT/12:00 noon ET on January 10, 2011. The presentation will contain an update on IMGN901 development plans, including current plans related to Merkel cell carcinoma.
